Skip to search formSkip to main contentSkip to account menu

NSC-655649

Known as: NSC 655649 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
PurposeABCG2 overexpression has been linked to resistance to topoisomerase inhibitors, leading us to examine the potential… 
2005
2005
Purpose: To evaluate the feasibility of administering NSC 655649, a water-soluble rebeccamycin analogue that inhibits both… 
2003
2003
Objective: Rebeccamycin analog (NSC-655649) is an antibiotic with antitumor properties demonstrated in preclinical and phase I… 
2003
2003
The analog, rebeccamycin tartrate salt (NSC 655649, Cancer Therapy Evaluation Program, National Cancer Institute) has broad… 
2002
2002
PURPOSE NSC 655649 was given in both single- and multiple-dose formats, to characterize maximum tolerated dose (MTD), toxicity… 
2001
2001
PURPOSE To assess the feasibility of administering NSC 655649, a water-soluble, rebeccamycin analog with topoisomerase inhibitory… 
2001
2001
PURPOSE Rebeccamycin analog (NSC 655649) is active against a variety of both solid and nonsolid tumor cell lines. We performed a…